FMP
NASDAQ
5.2 USD
-0.01 (-0.192%)
Dr. Mahesh V. Patel Ph.D.
Healthcare
Biotechnology
https://www.lipocine.com
NASDAQ
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial ...
0001535955
US53630X2036
53630X104
675 Arapeen Drive
801 994 7383
US
17
Oct 22, 2013
0001535955
NASDAQ
Biotechnology
Healthcare
53630X104
US53630X2036
US
5.2
1.02
29.16k
27.64M
-
2.31-5.95
0.9
-
-
-
-
-1.66
-
https://www.lipocine.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.